The only 'news' item I could find was in BIOWORLD Today,...

The only 'news' item I could find was in BIOWORLD Today, released on 28 August. It was in the 'other news to note' section:

"Antisense Therapeutics Ltd., of Melbourne, Australia, and Isis Pharmaceuticals Inc., of Carlsbad, Calif., began a Phase I trial of ATL1102 (ISIS 107248) for multiple sclerosis, the first antisense drug for that indication. ATL1102 inhibits VLA-4 (very late antigen- 4), a process the companies said results in positive effects in multiple animal models of inflammatory diseases, including multiple sclerosis. The double-blinded, placebo-controlled study will evaluate the pharmacokinetic and safety profile of ATL1102 in about 40 healthy volunteers in London. Isis licensed the compound to Antisense Therapeutics two years ago. (See BioWorld Today, Dec. 21, 2001.) "

Disclosure: I own ANPO